Treace Medical Concepts appoints Betsy Hanna and Deepti Jain to Board of Directors

TREACE MEDICAL CONCEPTS, INC.

Appointments effective October 1, 2021; Hanna as Class II director (term to 2023), Jain as Class I (term to 2022).
Hanna to serve on Compensation and NCG Committees; Jain on Audit and NCG Committees.
Hanna is President/CEO of Clinical Genomics, former J&J Vision Care VP; MBA from Harvard.
Jain was President of IngenioRX (Anthem), COO of Pharmacy Solutions; MBA from Baruch College.
Both determined independent under Nasdaq rules; no related-party transactions disclosed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Betsy Hanna

director

TMCI · TREACE MEDICAL CONCEPTS, INC.

Effective: 2021-10-01
Filed: October 4, 2021, 7:59 PM ET

appointed Betsy Hanna and Deepti Jain to the Company’s Board effective October 1, 2021.

Appointed

Deepti Jain

director

TMCI · TREACE MEDICAL CONCEPTS, INC.

Effective: 2021-10-01
Filed: October 4, 2021, 7:59 PM ET

appointed Betsy Hanna and Deepti Jain to the Company’s Board effective October 1, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Betsy Hanna was appointed as director at TREACE MEDICAL CONCEPTS, INC..

Action: appointed
Role: director

Exact text from the filing

appointed Betsy Hanna and Deepti Jain to the Company’s Board effective October 1, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Deepti Jain was appointed as director at TREACE MEDICAL CONCEPTS, INC..

Action: appointed
Role: director

Exact text from the filing

appointed Betsy Hanna and Deepti Jain to the Company’s Board effective October 1, 2021.

View on SEC.gov

TREACE MEDICAL CONCEPTS, INC. filing history →

Source: SEC EDGAR

accession 0001564590-21-049869

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.